FDA (CDER)
GUIDANCE DRAFT
Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing
Published: 9/2/2026Detected: 10/8/2026
Summary preview
Clarifies how pharmacokinetic (PK) studies should be designed and analyzed to evaluate drug exposure in patients with impaired hepatic function, with the goal of reducing uncertainty in dosing recommendations.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountclinical
safety
labeling
gastroenterology
cardiology
infectious_disease
neurology
oncology
#pharmacokinetics
#hepatic impairment
#dose adjustment
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry10/30/2026
- Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle10/20/2026
- Regulatory Considerations for Prescription Drug Use-Related Software10/20/2026
- Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators10/19/2026
- Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers10/9/2026